Production (Stage)
LENZ Therapeutics, Inc.
LENZ
$31.96
$1.665.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.77% | 44.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.21% | 17.61% | |||
| Operating Income | -11.21% | -17.61% | |||
| Income Before Tax | -15.56% | -23.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.55% | -23.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.55% | -23.86% | |||
| EBIT | -11.21% | -17.61% | |||
| EBITDA | -11.15% | -17.51% | |||
| EPS Basic | -15.41% | -22.43% | |||
| Normalized Basic EPS | -15.40% | -22.38% | |||
| EPS Diluted | -15.41% | -22.43% | |||
| Normalized Diluted EPS | -15.40% | -22.38% | |||
| Average Basic Shares Outstanding | 0.12% | 1.18% | |||
| Average Diluted Shares Outstanding | 0.12% | 1.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||